Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events

Vaccine. 2009 May 14;27(22):2954-8. doi: 10.1016/j.vaccine.2009.02.106. Epub 2009 Mar 13.


Determining incidence rates of potential adverse events before and after an immunisation programme is initiated, provides a useful framework for the evaluation of vaccine safety concerns. Human papillomavirus vaccination (HPV) of adolescent girls has recently been introduced in Denmark. Using a nationwide hospitalisation registry we estimated incidence rates of immune-mediated disorders before HPV vaccination in a cohort of 418,289 Danish girls aged 12-15 years. We further estimated the expected number of cases of immune-mediated disorders occurring in temporal relationship to a hypothetical HPV vaccination schedule purely by chance. Our results and analytical approach provides a framework for the evaluation of adverse event reports following immunisation of adolescent girls.

MeSH terms

  • Adolescent
  • Autoimmune Diseases / epidemiology
  • Child
  • Denmark
  • Female
  • Humans
  • Hypersensitivity / epidemiology
  • Incidence
  • Papillomavirus Infections / prevention & control*
  • Papillomavirus Vaccines / administration & dosage
  • Papillomavirus Vaccines / adverse effects*
  • Papillomavirus Vaccines / immunology


  • Papillomavirus Vaccines